Company intelligence / Profile preview
Aravax
Melbourne, Victoria, Australiaaravax.com.au ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Aravax has completed recruitment for its Phase 2 study of PVX108 for peanut allergy treatment. The study is being conducted in Australia and the USA with results expected in H1 2026[6]. The company is approaching Phase 3 development for its lead candidate PVX108[5].
- Therapeutic areas
- Immunology
- Modalities
- Peptide-based immunotherapies
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Aravax.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aravax.